Fresh out of 6 Dimensions' incubator, Curon launches with $150M and backing from Boyu, Temasek
The latest mega-round in the China biotech scene features some of the hottest VCs — and a pretty mysterious startup.
Curon Biopharmaceuticals has reaped $150 million in a Series A round that pulled in 6 Dimensions Capital, Boyu Capital and Temasek.
The Shanghai-based biotech was incubated by 6 Dimensions, which noted in a press release that it currently holds “multiple” cancer immunotherapy assets — to be advanced into preclinical and clinical phases using the new round of funding. The money will also go toward expanding the pipeline, though it’s unclear exactly how.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.